ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Prospective Study |
Article Title |
Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Eun Hye Oh, Dae-Hyun Ko, Hyungil Seo, Kiju Chang, Gwang-Un Kim, Eun Mi Song, Myeongsook Seo, Ho-Su Lee, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang and Sang Hyoung Park |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Asan Institute for Life Sciences, Asan Medical Center, Seoul, South Korea |
2015-637 |
|
Corresponding Author |
Sang Hyoung Park, MD, PhD, Assistant Professor, Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. umdalpin@hanmail.net |
Key Words |
Infliximab; Drug effect; Antibody; Crohn’s disease; Drug monitoring |
Core Tip |
This study aimed to clarify the clinical impli-cations of infliximab trough levels (IFX-TLs) and antibodies to infliximab (ATI) levels. They were measured using prospectively collected samples in 138 Crohn’s disease (CD) patients being treated at Asan Medical Center, South Korea. Correlations between IFX-TLs/ATIs and the clinical activity (P < 0.001) were verified in the study. Our findings support the usefulness of IFX-TLs/ATI levels in treating CD patients receiving IFX in clinical practices. |
Publish Date |
2017-02-26 18:20 |
Citation |
Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol 2017; 23(8): 1489-1496 |
URL |
http://www.wjgnet.com/1007-9327/full/v23/i8/1489.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v23.i8.1489 |